[01] Mohamed Ait Erraisse, Department of Radiation Oncology, University Hospital Hassan II, Fez, Morocco. [02] Fatima Zahra Abboud, Department of Radiation Oncology, University Hospital Hassan II, Fez, Morocco. [03] Badr Alami, Department of Radiology, University Hospital Hassan II, Fez, Morocco. [04] Touria Bouhafa, Department of Radiation Oncology, University Hospital Hassan II, Fez, Morocco. [05] Khalid Hassouni, Department of Radiation Oncology, University Hospital Hassan II, Fez, Morocco.

This is a case of malignant melanoma of the choroid that occurred during pregnancy. This is a 32-year-old female mother of a daughter, and who is at 28 weeks of pregnancy with the diagnosis of malignant melanoma of the choroid on the decreasing of visual acuity and clinical and imaging findings. Given the diffuse involvement, an enucleation is performed with placement of an ocular prosthesis. Pathological examination confirmed the diagnosis of choroidal melanoma with positive posterior margin resection. Radiotherapy was then indicated but after delivery since no proton therapy is available. Intensity modulated radiation therapy (IMRT) was performed in a hypofractionated schedule. Reporting this observation is to discuss the difficulties of management in a pregnant woman and also the possible alternatives to the lack of material resources like proton therapy.

Melanoma, Choroid, Pregnancy, IMRT

[01] Zografos L, Uffer S. Tumeurs intraoculaires. Société Française d'Ophtalmologie et Masson, Paris, 2002: 281-313. [02] Gaudy marquestre C; Monestier S; Grobl J. Mélanome. EMC (Elsevier Masson SAS, Paris), Dermatologie, 98-595-A-10, 2007. [03] Shukla S, Acharya S, Dulani M. Pregnancy and melanoma. Journal of Clinical and Diagnostic Research. 2015 May, Vol-9 (5): ED09-ED10 [04] Charif chefchaouni M. Mélanome de l’iris et grossesse. Journal rançais d’Ophtalmologie Vol 26, N3- mars 2003 pp. 277-280 [05] Driscoll MS, Grant-Kels JM. Hormones, nevi and melanoma: an approach to the patient. J Am Acad Dermatol. 2007; 57: 919-931. [06] Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women’s Health Initiative randomized trials. J Natl Cancer Inst. 2011; 103: 1469-1475.
 [07] Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol. 2010; 28: 287-292. [08] Laver NV; McLaughlin ME; Duker JS. Ocular Melanoma. Arch Pathol Lab Med. 2010; 134: 1778–1784 [09] Tarlan B; Kiratli H;. Uveal Melanoma: Current Trends in Diagnosis and Management. Turk J Ophtalmol. 2016 Jun; 46 (3): 123–137 [10] Mudhar HS; Dherty R; Salawu A; Sisley K; Rennie IG. Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations. Br J Ophtalmol 2013 Jul; 97 (7): 924-8 [11] Stodell M; Thompson JF; Emmett L; Uren RF; Kapoor R; Saw RPM. European Journal of Surgical Oncology (EJSO); Volume 43, Issue 8 August 2017, Pages 1517-1527 [12] Shields et al. "Choroidal nevus transformation into melanoma: analysis of 2514 consecutive cases." Arch Ophthalmol. 2009 Aug; 127 (8): 981-7 [13] Margo CE. "The Collaborative Ocular Melanoma Study: an overview. Cancer Control.". Cancer Control 2004 Sep-Oct; 11 (5): 304-9. [14] Stannard C; Sauerwein W; Maree G; Lecuona K. Radiotherapy for ocular tumours. Eye (Lond). 2013 Feb; 27 (2): 119–127. [15] Kaliki S; Shields CL; Shields JA Uveal melanoma: Estimating prognosis. Indian J Ophthalmol. 2015 Feb; 63 (2): 93–102.